Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037383 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| SCHEMBL21423960 | 0.78 | KDM4E (0.41) | TSHRHSD17B10MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL2358722 | 0.76 | GBA1 (0.38) | DGAT1MTNR1AMTNR1BMMP2MMP9 | |
| SCHEMBL21424270 | 0.76 | P2RX7 (0.40) | DGAT1 | |
| SCHEMBL25579751 | 0.76 | DGAT1 (0.41) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL25579749 | 0.76 | DGAT1 (0.41) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL22396008 | 0.75 | DGAT1 (0.37) | DGAT1MTNR1AMTNR1BMMP2MMP9 | |
| SCHEMBL13695965 | 0.75 | DGAT1 (0.45) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL26770649 | 0.75 | F2RL1 (0.40) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL19153067 | 0.75 | P2RX7 (0.34) | DGAT1MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO INC (US) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | CD47, CD4, BST2 | DGAT1 2035/4885USP2 1953/4885ALOX15 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.